NCAPG2 Maintains Cancer Stemness and Promotes Erlotinib Resistance in Lung Adenocarcinoma. [PDF]
Cancers (Basel), 2022 Simple Summary This study investigated the relationship between erlotinib resistance and stemness in lung adenocarcinoma. NCAPG2 was identified as an erlotinib resistance gene and maintained the stemness of lung adenocarcinoma.
Jiang S +9 more
europepmc +4 more sources
Suppression of c-MET overcomes erlotinib resistance in tongue cancer cells. [PDF]
Onco Targets Ther, 2018 Background Erlotinib is a commonly used molecular-targeted drug for the treatment of tongue cancer. However, the development of acquired resistance to erlotinib hampers its therapeutic use.
Huang K, Liu D.
europepmc +6 more sources
Increased expression of miR‐641 contributes to erlotinib resistance in non‐small‐cell lung cancer cells by targeting NF1 [PDF]
Cancer Medicine, 2018 Epidermal growth receptor (EGFR)‐targeted tyrosine kinase inhibitors (TKIs) have emerged as first‐line drugs for advanced non‐small‐cell lung cancer (NSCLC) patients with EFGR mutations.
Juan Chen +4 more
doaj +3 more sources
AKR1C3 as a therapeutic target to overcome erlotinib resistance in lung adenocarcinoma. [PDF]
Mil Med ResCho WC +7 more
europepmc +5 more sources
Comparative metabolomic analysis of HPAC cells following the acquisition of erlotinib resistance. [PDF]
Oncol Lett, 2017 Pancreatic cancer is one of the most lethal types of cancer, due to difficulty in early detection and the limited efficacy of available treatments. Erlotinib is used to inhibit the epidermal growth factor receptor for the treatment of pancreatic cancer ...
Lee S +4 more
europepmc +5 more sources
M6A associated TSUC7 inhibition contributed to Erlotinib resistance in lung adenocarcinoma through a notch signaling activation dependent way. [PDF]
J Exp Clin Cancer Res, 2021 The small tyrosine kinase inhibitors (TKIs) subversively altered the lung cancer treatments, but patients will inevitably face the therapy resistance and disease recurrence. We aim to explore the potential roles of non-coding RNAs in sensitizing the TKIs
Li K +10 more
europepmc +2 more sources
Identification of microRNAs that promote erlotinib resistance in non-small cell lung cancer. [PDF]
Biochem Pharmacol, 2021 Lung cancer is the leading cause of cancer-related deaths, demanding improvement in current treatment modalities to reduce the mortality rates. Lung cancer is divided into two major classes with non-small cell lung cancer representing ~84% of lung cancer
Pal AS, Bains M, Agredo A, Kasinski AL.
europepmc +2 more sources
GLI1 activation is a key mechanism of erlotinib resistance in human non-small cell lung cancer. [PDF]
Oncol Lett, 2020 Lung cancer is the leading cause of cancer-associated death worldwide. In recent years, the advancement of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) targeted therapies has provided clinical benefits for lung cancer patients ...
Dong Z +10 more
europepmc +2 more sources
Cells, 2023 Oral squamous cell carcinoma (OSCC) frequently carries high epidermal growth factor receptor (EGFR) expression. Erlotinib, a small molecule tyrosine kinase inhibitor (TKI), is an effective inhibitor of EGFR activity; however, resistance to this drug can ...
Chien-Yi Chan +5 more
doaj +2 more sources
LHX6 Affects Erlotinib Resistance and Migration of EGFR-Mutant Non-Small-Cell Lung Cancer HCC827 Cells Through Suppressing Wnt/β-Catenin Signaling. [PDF]
Onco Targets Ther, 2020 Background miR-214 has been reported to contribute to erlotinib resistance in non-small-cell lung cancer (NSCLC) through targeting LHX6; however, the molecular mechanisms underlying the involvement of LHX6 in mediating the resistance to EGFR-TKIs in ...
Wang Q +7 more
europepmc +2 more sources